| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/23/2004 | US20040186175 Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds |
| 09/23/2004 | US20040186174 Hydroxydiphenyl ether compounds |
| 09/23/2004 | US20040186173 Reacting 2-cyano-N-(4-trifluoromethylphenyl)acetamide in the presence of acetic anhydride and sodium hydroxide, to form 2-cyano-3-hydroxy-N-((4-trifluoromethyl)phenyl)but-2-enamide |
| 09/23/2004 | US20040186172 reacting potassium tetrachloroplatinate K2PtCl4 with trans-I-1,2-cyclohexanediamine to obtain dichloro(trans-I-1,2-cyclohexanediamine)-platinum (II), adding silver nitrate to obtain diaquo(trans-I-1,2-cyclohexanediamine)-platinum (II), filtering and purifying oxaliplatin by recrystallization |
| 09/23/2004 | US20040186169 for inhibition of the insulin-like growth factor-1 receptor (IGF-1R); for treatment of IGF-IR dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly; picropodophyllin |
| 09/23/2004 | US20040186168 Such as spiroadamantane on one side and 4-substituted spiro-cyclohexyl on other side; structurally simple, nontoxic, easy synthesis, potent parasiticides |
| 09/23/2004 | US20040186166 using cannabinoid compounds, such as ajulemic acid for treatment of disorders involving the receptor (PPAR gamma ) such as autoimmune or inflammatory disorders like rheumatoid arthritis and diabetes |
| 09/23/2004 | US20040186164 Pharmaceutical composition comprising citrulline |
| 09/23/2004 | US20040186163 Novel combination |
| 09/23/2004 | US20040186162 preparation of the amorphous inhibitor and its hydrates of desired particle size which comprises dissolving the inhibitor in a hydroxylic solvent (methanol), then removing the solvent by freeze-drying |
| 09/23/2004 | US20040186159 used to treat glaucomatous optic neuropathy and/or lower and control intraocular pressure (IOP) associated with normal-tension glaucoma, ocular hypertension, and/or glaucoma in warm blooded animals, including man |
| 09/23/2004 | US20040186158 Novel composition of carvedilol |
| 09/23/2004 | US20040186157 inhibiting kinases; for treating or preventing neoplasia, rheumatoid arthritis, pulmonary fibrosis, myelofibrosis, abnormal wound healing, atherosclerosis, or restenosis, alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, stroke, ischaemia, Huntington's disease, AIDS dementia |
| 09/23/2004 | US20040186155 Combination therapy for the treatment or prevention of migraine |
| 09/23/2004 | US20040186154 treating or preventing a hypercholesterolemia-related or an inflammation-related condition ; apical sodium co-dependent bile acid transport inhibitor and an amount of a cyclooxygenase-2 (COX-2) selective inhibitor or its prodrug; kits |
| 09/23/2004 | US20040186150 4-{5-[4-(5-Isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine or N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine (DW-1350); a leukotriene-B4 receptor antangonist; inhibiting osteoclastic bone absorption |
| 09/23/2004 | US20040186145 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| 09/23/2004 | US20040186144 Use of vitamin B6 to mitigate visual field defects associated with the use of GABAergic drugs in mammals |
| 09/23/2004 | US20040186143 Lactams as modulators of chemokine receptor activity |
| 09/23/2004 | US20040186142 Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC- chemokine receptor ligands |
| 09/23/2004 | US20040186140 Cyclic derivatives as modulators of chemokine receptor activity |
| 09/23/2004 | US20040186139 Process for preparation of crystalline form-1 of pantoprazole sodium sesquihydrate |
| 09/23/2004 | US20040186136 E.g., mono-, poly- or perdeuteriated tolperisone and eperisone; appreciably better pharmacokinetic and/or pharmacodynamic properties than the undeuterated compounds; muscular disorders; muscle relaxants (skeletal); antispasmodic agents; vasodilation |
| 09/23/2004 | US20040186134 Inhibitors of Factor Xa are useful as anticoagulants in the treatment of cardiovascular disorders associated with thromboses; e.g., 1,1-dimethylethyl 1-[1-(-2-(-3-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonylamino]-2-oxo-piperidin-1-yl)-acetyl)-pyrrolidin-2- yl-methyl]-pyrrolidin-3-yl}-methyl-carbamate |
| 09/23/2004 | US20040186133 preferably antagonists used in the therapeutic and/or preventive treatment of disfunctions of the heart, kidney, respiratory system, central nervous system |
| 09/23/2004 | US20040186131 Viricides and antiinflammatory agents based on quinoline and 1,4-oxazino(2,3,4-ij)quinoline compounds, e.g., N-(4-chlorobenzyl-6-(4-morpholinylmethyl)-4-oxo-1-phenyl-1,4-dihydro-3-quinolinecarboxamide; herpes virus 1,2 and 8; varicella-zoster virus |
| 09/23/2004 | US20040186130 Delivery of muscle relaxants through an inhalation route |
| 09/23/2004 | US20040186129 2-Aroylimidazole compounds for treating cancer |
| 09/23/2004 | US20040186128 Amide substituted imidazopyridines |
| 09/23/2004 | US20040186127 E.g., 7-(5-(2-(cyclohexylmethylamino)ethyl)indol-2-yl), 2-methyl-3H-imidazo(4,5-b)pyridine; antiinflammatory agents; antiproliferative agents; autoimmune diseases; reperfusion injuries; osteoporosis; bone disorders; antimetastasis agents |
| 09/23/2004 | US20040186126 Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use |
| 09/23/2004 | US20040186124 Anticarcinogenic agents, antitumor agents treating cancer of breast, head , neck, gastrointestinal or stomach, leukemia, ovaries, bronchi, lung or pancreas |
| 09/23/2004 | US20040186122 Method of treating acute pain with a unitary dosage form comprising ibuprofin and oxycodone |
| 09/23/2004 | US20040186121 Tamper-resistant oral opioid agonist formulations |
| 09/23/2004 | US20040186120 for treatment of focal distonia, tremors, and parkinson's disease |
| 09/23/2004 | US20040186118 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
| 09/23/2004 | US20040186115 for treatment of proliferative, cardiac, neurodegenerative, and autoimmune disorders |
| 09/23/2004 | US20040186114 Cytokine inhibitors |
| 09/23/2004 | US20040186113 Heterocyclic amines for the treatment of conditions associated with gsk-3 |
| 09/23/2004 | US20040186112 Polymorphic forms of dihydrochloride salts of cetirizine and processes for preparation thereof |
| 09/23/2004 | US20040186111 Therapeutic agents useful for treating pain |
| 09/23/2004 | US20040186106 such as (S)-N-{{(1R, 2R)-2-{4-{[2-(4-Methyl-piperazin-1-yl)-benzimidazol-1-yl]methyl}-phenyl}-cyclohex-1-yl} carbonyl}-phenylglycinamide; for treatment of ischemic brain disorders |
| 09/23/2004 | US20040186105 admixing low viscosity pregelatinized starch with low water soluble cyclooxygenase-2 inhibitory drug such as celecoxib |
| 09/23/2004 | US20040186104 Novel pyridinone and related heterocyclic derivatives |
| 09/23/2004 | US20040186103 Substituted alkyl amido piperidines |
| 09/23/2004 | US20040186102 such as {4-Chloro-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine for treatment of cardiovascular disorders, kidney disorders, pain and inflammation |
| 09/23/2004 | US20040186101 such as 6-(3-Chlorophenyl)-4,4-dimethyl-1,4-dihydrobenzo[d][1,3]oxazin-2-one; hormone replacement therapy |
| 09/23/2004 | US20040186100 X-ray diffraction patterning; for treatment of migraine, rheumatoid arthritis, asthma, bronchial hyperreactivity, allergic rhinitis, ocular inflammatory diseases, and oedema; for treating drug abuse |
| 09/23/2004 | US20040186099 Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine |
| 09/23/2004 | US20040186098 Method for preventing and treating hearing loss using sensorineurotrophic compounds |
| 09/23/2004 | US20040186096 Drugs comprising phospholipase enzyme inhibitor; chemical synthesis; anaphylaxis, allergic inflammation, asthma, rhinitis, bronchitis, pneumonia, adult respiratory distress syndrome, inflammatory intestine disorder, Crohn's disease, ulcerative colitis, ischemia/reperfusion injuries, vasculitis |
| 09/23/2004 | US20040186095 Harringtonine and homoharringtonine are cephalotaxane drugs; natural or synthetic products from plant extracts; pure crystals; treating leukemia, tumors, parasitic disease, or as immunosuppressant, antitumor agents |
| 09/23/2004 | US20040186090 New amidino derivatives and their use as thrombin inhibitors |
| 09/23/2004 | US20040186089 Compounds useful in the treatment of anthrax |
| 09/23/2004 | US20040186087 Siderophore conjugates of photoactive dyes for photodynamic therapy |
| 09/23/2004 | US20040186086 Estetrol and estetrol-like substances have relatively low estrogenic potency, metabolic stability, long half-life; triene steroids |
| 09/23/2004 | US20040186085 Cosmetic mixture comprising DHEA and a metabolic or chemical derivative thereof, dipropylene glycol for inhibiting recrystallization of DHEA; preventing or treating actinic skin ageing, skin disorders, pigmentation disorders of the skin or hair, dandruff, hair loss |
| 09/23/2004 | US20040186084 Sterile aqueous composition comprising triamcinolone acetonide, and tonicity-adjusting agents, pH-adjusting agents to provide a pH of between about 5 and 7.5; treating diabetic macular edema and related illness; intravitreal injection |
| 09/23/2004 | US20040186083 Combination of an aldosterone receptor antagonist and an endothelin receptor antagonist and/or endothelin converting enzyme inhibitor |
| 09/23/2004 | US20040186082 Applying a vitamin D precursors followed by exposure to ultraviolet radiation or blue light; calcitriol and calcitriol analog precursors, NFkappaB inhibitors, vitamin D receptor stimulants and/or photosensitizers |
| 09/23/2004 | US20040186081 Naaladase inhibitors for treating opioid tolerance |
| 09/23/2004 | US20040186080 Beta 2-adrenergic receptor agonists |
| 09/23/2004 | US20040186078 Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 09/23/2004 | US20040186076 Pharmaceutical complex |
| 09/23/2004 | US20040186074 including 2-hydroxylpropyl- beta -cyclodextrin for reducing toxicity; a stable, concentrated solution has ifosfamide concentrations as high has 1,1000 mg/ml; antitumor agents |
| 09/23/2004 | US20040186072 Use of esters of long-chain fatty acids for treatment of autoimmune diseases |
| 09/23/2004 | US20040186066 Method of treatment with nelfinavir |
| 09/23/2004 | US20040186065 Forms of 5-azacytidine |
| 09/23/2004 | US20040186064 additive-free, isotonic inhalant of pH 4.0 to 5.5; improved shelf-life at room temperature; acute and chronic endobronchial infections; cystic fibrosis |
| 09/23/2004 | US20040186062 Formulation for use in the prevention and treatment of carbohydrate induced diseases and conditions |
| 09/23/2004 | US20040186061 Novel derivatives of 3,3-diphenylpropylamines |
| 09/23/2004 | US20040186049 Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
| 09/23/2004 | US20040186048 Gene regulation therapy involving ferritin |
| 09/23/2004 | US20040186046 Treatment of type 1 diabetes with PDE5 inhibitors |
| 09/23/2004 | US20040186031 hand cleaning compounds comprising mixtures of microbiocides having phenols such as chloroxylenol and/or triclosan, and low viscosity surfactants |
| 09/23/2004 | US20040185546 enzyme inhibitor for selectin mediated binding events and methods of treating disease conditions using animal models; genetic engineering |
| 09/23/2004 | US20040185510 Administering a composition sufficient for external imaging, a peptide of given formula; radioactive scanning or by magnetic resonance; use for detecting metastasis; kits |
| 09/23/2004 | US20040185503 Administering peroxisome proliferator-activated receptor agonist; assaying substance for up-regulating the expression of fatty acid-binding protein; glomerulonephritis, nephrotic syndrome, focal glomerulosclerosis |
| 09/23/2004 | US20040185433 such as acyclovir/valaciclovir or penciclovir/famciclovir, and an immunosuppressant, as a combined preparation for simultaneous, separate or sequential use in the treatment and/or prevention |
| 09/23/2004 | US20040185257 Microbiocide surfaces; contact antiseptic |
| 09/23/2004 | US20040185125 Daily administering a mixture of zinc salt, cyclo-Hispro (soybean protein product), arachidonic acid; treating hypertension, high cholesterol, weight control; nutritional supplements, foods |
| 09/23/2004 | US20040185119 by administering supplemental vitamins; dosage forms such as omeprazole and vitamin B12 |
| 09/23/2004 | US20040185117 Cephalotaxine alkaloid compositions and uses thereof |
| 09/23/2004 | US20040185112 incorporation of a pressure nozzle and a diffuser plate to improve the flow of drying gas and a drying chamber extension to increase drying time, such improvements leading to the formation of homogeneous solid dispersions of drugs in concentration-enhancing polymers |
| 09/23/2004 | US20040185110 forming a co-dissolved solution of a compatible aid and bioactive agent, and film forming or particle forming so the bioactive agent is crystalline; improved bioavailability of COX-2 inhibitors such as (Z)-3-[1-(4-bromophenyl)-1-(4-methylsulfonylphenyl) methylidene]-dihydrofuran-2-one |
| 09/23/2004 | US20040185105 Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| 09/23/2004 | US20040185102 Cholesteryl ester transfer protein (CETP) such as torcetrapib; 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase); improved chemical stability of the HMG-CoA reductase inhibitor |
| 09/23/2004 | US20040185100 Dosage form with two regions, an extended release region of an NSAID such as diclofenac and an immediate release gastroprotective prostaglandin; osteoarthritis or rheumatoid arthritis; allowing a one a day or twice a day dosing into humans; packaging to minimize oxygen permeation |
| 09/23/2004 | US20040185099 Multiparticulate bisoprolol formulation |
| 09/23/2004 | US20040185098 Making oral dosage form by forming granules comprising oxycodone hydrochloride, alkyl cellulose and polymethacrylate, and drying said granules |
| 09/23/2004 | US20040185096 Melt-extrusion multiparticulates |
| 09/23/2004 | US20040185095 Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release |
| 09/23/2004 | US20040185094 Intermediate conductance calcium-activated potassium (IKCa) channel modulator; relaxants of corpus cavernosal smooth muscle; drug screening |
| 09/23/2004 | US20040185092 Enteric coated hard or soft capsule; acid resistance; dissolves in neutral to alkaline media; gastrointestinal disorders |
| 09/23/2004 | US20040185086 Varying ratios of acrylyol-modified dextran molecules and acrylyol-modified hyaluronan crosslinked to form hydrogel conjugate; degradable by hydrolysis; prevention of surgical adhesions, controlled drug delivery, tissue and medical equipment coatings |
| 09/23/2004 | US20040185077 Applying dimethylaminoethanol, tyrosine, and sulfur compound such as lipoic acid, glutathione, sulfur, resorcinol, resorcinol monoacetate, and/or sulfacetamide; skin sensitivity; side effect reduction |
| 09/23/2004 | US20040185076 Treatment of acne using alkonolamine compositions |
| 09/23/2004 | US20040185069 Hydroxycitric acid derivatives for body slimming and tone firming compositions |
| 09/23/2004 | US20040185065 Warming and nonirritating lubricant compositions and method of comparing irritation |
| 09/23/2004 | US20040185052 Antitumor agents; leukemia; |